In preclinical studies published in Nature Cancer (July 2022), our team reported small molecules designed to disrupt protein-folding homeostasis and increase endoplasmic-reticulum (ER) stress in tumor cells. In the models studied, this mechanism was associated with loss of tumor-cell viability.
Status: ERX-315 is being evaluated in an open-label, dose-escalation Phase 1 study in Australia (NCT06533332) to characterize safety, pharmacokinetics, tolerability, and to identify a recommended Phase 2 dose. Potential risks and benefits are unknown; adverse events and dose-limiting toxicities are being studied in Phase 1.
Note: These findings are preclinical and may not predict clinical outcomes.
At Etira, we’re taking a different approach. Our new investigational drug ERX-315 hopes to change the paradigm in cancer therapy by targeting a fundamental vulnerability present in most advanced cancer cells, regardless of type. By targeting the entire complexity of cancer rather than just one cell type, ERX-315 has the possibility to overcome tumor heterogeneity.
We Fight Harder.
Mechanism focus: Small molecules designed to increase endoplasmic-reticulum (ER) stress in tumor cells by disrupting protein-folding homeostasis; LIPA-dependent biology was reported in a 2022 preclinical publication in Nature Cancer.
Evidence to date (preclinical): In vitro and in vivo models showed increased ER stress associated with loss of tumor-cell viability. Findings are preclinical and may not predict clinical outcomes.
This page shares scientific information about Etira’s investigational program. It is not promotional. Findings are preliminary; preclinical results may not predict clinical outcomes. ERX-315 is investigational and has not been approved by the U.S. Food and Drug Administration (FDA). Safety and efficacy have not been established.
Our
Approach
0{{current_slide_index}} | 0{{total_slide_count}}
Where to find us
Dallas Office:
3033 Irving Blvd,
Dallas. TX. 75247
Mailing Address:
3060 Pegasus Park Dr.
Dallas. TX. 75247